JP2016512250A5 - - Google Patents

Download PDF

Info

Publication number
JP2016512250A5
JP2016512250A5 JP2016500489A JP2016500489A JP2016512250A5 JP 2016512250 A5 JP2016512250 A5 JP 2016512250A5 JP 2016500489 A JP2016500489 A JP 2016500489A JP 2016500489 A JP2016500489 A JP 2016500489A JP 2016512250 A5 JP2016512250 A5 JP 2016512250A5
Authority
JP
Japan
Prior art keywords
pharmaceutical formulation
hours
particles
particle size
sulfonic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016500489A
Other languages
English (en)
Japanese (ja)
Other versions
JP6314206B2 (ja
JP2016512250A (ja
Filing date
Publication date
Priority claimed from US13/832,694 external-priority patent/US20140271892A1/en
Application filed filed Critical
Publication of JP2016512250A publication Critical patent/JP2016512250A/ja
Publication of JP2016512250A5 publication Critical patent/JP2016512250A5/ja
Application granted granted Critical
Publication of JP6314206B2 publication Critical patent/JP6314206B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016500489A 2013-03-15 2014-02-28 樹脂酸フェニレフリン粒子 Expired - Fee Related JP6314206B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/832,694 US20140271892A1 (en) 2013-03-15 2013-03-15 Phenylephrine resinate particles having good auc
US13/832,694 2013-03-15
PCT/US2014/019301 WO2014149526A1 (en) 2013-03-15 2014-02-28 Phenylephrine resinate particles

Publications (3)

Publication Number Publication Date
JP2016512250A JP2016512250A (ja) 2016-04-25
JP2016512250A5 true JP2016512250A5 (enExample) 2017-03-09
JP6314206B2 JP6314206B2 (ja) 2018-04-18

Family

ID=50272778

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016500489A Expired - Fee Related JP6314206B2 (ja) 2013-03-15 2014-02-28 樹脂酸フェニレフリン粒子

Country Status (13)

Country Link
US (1) US20140271892A1 (enExample)
EP (1) EP2968223B1 (enExample)
JP (1) JP6314206B2 (enExample)
CN (2) CN105263483A (enExample)
AU (1) AU2014238059B2 (enExample)
BR (1) BR112015022975B1 (enExample)
CA (1) CA2906357C (enExample)
IL (1) IL241050B (enExample)
MX (1) MX383890B (enExample)
PH (1) PH12015502066A1 (enExample)
RU (1) RU2675788C2 (enExample)
UA (1) UA116372C2 (enExample)
WO (1) WO2014149526A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41152A (fr) 2014-12-12 2017-10-17 Johnson & Johnson Consumer Inc Procédé de fabrication de particules de résinate de phényléphrine ; particules de résinate de phényléphrine et utilisation des particules de résinate de phényléphrine dans des formulations pharmaceutiques
CN109187832B (zh) * 2018-09-30 2021-07-30 华润三九医药股份有限公司 Lc-ms/ms测定去氧肾上腺素浓度的方法及样品的前处理方法
KR20230127266A (ko) * 2020-12-29 2023-08-31 애브비 인코포레이티드 서방형 우파다시티닙 제형
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH693625A5 (it) * 1999-02-18 2003-11-28 Inpharma Sa Composizioni farmaceutiche contenenti composti ad attività promotrice di assorbimento di principi attivi.
WO2003020242A1 (en) * 2001-08-29 2003-03-13 Srl Technologies, Inc. Sustained release preparations
US20040265373A1 (en) * 2003-06-27 2004-12-30 David Wynn Soft tablet containing high molecular weight cellulosics
US20050266032A1 (en) * 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US9492541B2 (en) * 2004-09-14 2016-11-15 Sovereign Pharmaceuticals, Llc Phenylepherine containing dosage form
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
KR101495146B1 (ko) * 2006-03-16 2015-02-24 트리스 파마 인코포레이티드 약물 - 이온교환 수지 복합체를 함유하는 변형 방출 제제
US20080064694A1 (en) * 2006-09-11 2008-03-13 Auriga Laboratories, Inc. Multi-Phase Release Methscopolamine Compositions
JP2010510320A (ja) * 2006-11-21 2010-04-02 マクニール−ピーピーシー・インコーポレーテツド 改変型放出鎮痛性懸濁液
US8323695B2 (en) * 2007-08-13 2012-12-04 Mcneil-Ppc, Inc. Method for stabilizing phenylephrine
CN102119027A (zh) * 2008-06-26 2011-07-06 麦克内尔-Ppc股份有限公司 含有药物活性剂的包衣颗粒
WO2010115015A1 (en) * 2009-04-03 2010-10-07 Coating Place, Inc. Modified-release pharmaceutical drug composition
US20130230587A1 (en) * 2010-11-10 2013-09-05 Rubicon Research Private Limited Sustained release compositions

Similar Documents

Publication Publication Date Title
JP7019727B2 (ja) インフルエンザの治療方法
Li et al. Inhibition of H1N1 influenza virus-induced apoptosis by functionalized selenium nanoparticles with amantadine through ROS-mediated AKT signaling pathways
Li et al. Silver nanoparticle based codelivery of oseltamivir to inhibit the activity of the H1N1 influenza virus through ROS-mediated signaling pathways
Pourshahab et al. Preparation and characterization of spray dried inhalable powders containing chitosan nanoparticles for pulmonary delivery of isoniazid
Li et al. Inhibition of H1N1 influenza virus-induced apoptosis by selenium nanoparticles functionalized with arbidol through ROS-mediated signaling pathways
Wang et al. Antiviral activity of puerarin as potent inhibitor of influenza virus neuraminidase
JP2012503668A5 (enExample)
JP2014528474A5 (enExample)
JP2016512250A5 (enExample)
JP2016518388A5 (enExample)
JP2010515682A5 (enExample)
BRPI0906851B1 (pt) Formulação em aerossol com sais de aminoácidos básicos de ácido acetilsalicílico e uso de sais de aminoácidos básicos de ácido acetilsalicílico no tratamento de infecções virais
JP2015515968A5 (enExample)
CN104288170B (zh) 松果菊苷在抗肿瘤药物中的应用
RU2015144181A (ru) Частицы резината фенилэфрина
Mokra et al. N-Acetylcysteine in the Treatment of Acute Lung Injury: Perspectives and Limitations
JP2011500731A5 (enExample)
CN103705537A (zh) 硫化氢及其供体硫氢化钠在制备治疗脂质代谢紊乱药物中的用途
MX373699B (es) Composicion farmaceutica que contiene budesonida y formoterol.
CN102772398A (zh) 二氢杨梅素在制备防治流感药物中的应用
CN102670532B (zh) 伊潘立酮药物组合物及其制备方法
CN103341026B (zh) 一种防治流感的组合物及其制剂制备方法和应用
CN103239401B (zh) 一种非诺贝特纳米混悬剂及其制备方法
CN104739761A (zh) 一种盐酸氨溴索毫微粒的制备方法
WO2018201920A1 (zh) 龙虎人丹在制备预防和/或治疗肝纤维化药物中的应用